Knapp, M, Windmeijer, F, Brown, J, Kontodimas, S, Tzivelekis, S, Maria Haro, J, et al on behalf of the SOHO Study Group.
Cost-utility analysis of treatment with olanzapine
compared with other antipsychotic treatments in patients with
schizophrenia in the pan-European SOHO study.
2008; 26: 341–58.
Barrett, B, Byford, S, Knapp, MJ. Evidence of cost-effective treatments for
depression: a systematic review. J Affect
Drummond, MF, Sculpher, MJ, Torrance, GW, O'Brien, BJ, Stoddart, GL. Methods for the Economic Evaluation of Health Care
Programmes (3rd edn). Oxford
University Press, 2005.
Sach, TH, Barton, GR, Doherty, M, Muir, K, Jenkinson, C, Avery, AJ. The relationship between BMI and health related
quality of life: comparing the EQ–5D, EuroQol VAS, and
SF–6D. Int J Obes Relat Metab Disord
2007; 31: 189–96.
Knapp, M, Thorgrimsen, L, Patel, A, Spector, A, Hallam, A, Woods, B, et al. Cognitive stimulation therapy for people with
dementia: cost-effectiveness analysis. Br J
2006; 188: 574–80.
McCrone, P, Risdale, L, Darbishare, L, Seed, P. Cost-effectiveness of cognitive behavioural therapy,
graded exercise and usual care for patients with chronic fatigue in
primary care. Psychol Med
2004; 34: 991–9.
Kennedy, TM, Chalder, T, McCrone, P, Darnley, S, Knapp, M, Jones, RH, et al. Cognitive behavioural therapy in addition to
antispasmodic therapy for irritable bowel syndrome in primary care:
randomised controlled trial. Health Technol
Priebe, S, Jones, G, McCabe, R, Briscoe, J, Wright, D, Sleed, M, et al. Effectiveness and costs of acute day hospital
treatment compared with conventional in-patient care. Randomised
controlled trial. Br J Psychiatry
2006; 188: 243–9.
Dixon, L, Hoch, JS, Clark, R, Bebout, R, Drake, R, McHugo, G, et al. Cost-effectiveness of two vocational
rehabilitation programs for persons with severe mental
illness. Psychiatr Serv
2002; 53: 1118–24.
Fenton, WS, Hoch, JS, Herrell, JM, Mosher, L, Dixon, L. Cost and cost-effectiveness of hospital vs
residential crisis care for patients who have serious mental
illness. Arch Gen Psychiatry
2002; 59: 357–64.
Beecham, J, Sleed, M, Knapp, M, Chiesa, M, Drahorad, C. The costs and effectiveness of two psychosocial
treatment programmes for personality disorder: a controlled
study. Eur Psychiatry
2006; 21: 102–9.
Byford, S, Knapp, M, Greenshields, J, Ukoumunne, OC, Jones, V, Thompson, S, et al (POMACT Group).
Cost-effectiveness of brief cognitive behaviour therapy
versus treatment as usual in recurrent deliberate self-harm: a
decision-making approach. Psychol Med
2003; 33: 977–86.
Hurst, NP, Kind, P, Ruta, D, Hunter, M, Stubbings, A. Measuring health-related quality of life in
rheumatoid arthritis: validity, responsiveness and reliability of EuroQol
1997; 36: 551–9.
Terwee, CB, Dekker, FW, Wiersinga, WM, Prummel, MF, Bossuyt, PMM. On assessing responsiveness of health-related
quality of life instruments: Guidelines for instrument
evaluation. Qual Life Res
2003; 12: 349–62.
National Institute for Health and Clinical Excellence.
Guide to the Methods of Technology Appraisal.
Fowler, D, Hodgekins, J, Painter, M, Reilly, T, Crane, C, Macmillan, I, et al. Cognitive behaviour therapy for improving
social recovery in psychosis: a report from the ISREP MRC Trial platform
study (Improving Social Recovery in Early Psychosis).
Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for
schizophrenia. Schizophr Bull
1987; 13: 261–76.
Beck, AT, Steer, RA. Beck Anxiety Inventory. The
Beck, AT, Steer, RA, Brown, GK. BDI–II Manual. The Psychological
Beck, AT, Steer, RA. Beck Hopelessness Scale Manual.
The Psychological Corporation,
Goldman, HH, Skodol, AE, Lave, TR. Revising axis V for DSM–IV: a review of measures of
social functioning. Am J Psychiatry
1992; 149: 1148–56.
Heinrichs, DW, Hanlon, TE, Carpenter, BN. The Quality of Life Scale: an instrument for rating
the schizophrenic deficit syndrome. Schizophr
1984; 10: 388–98.
American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders (4th revision, text revision)
Dolan, P, Gudex, C, Kind, P, Williams, A. A social tariff for the EuroQol: results from a UK general
population survey (Discussion Paper 138). Centre
for Health Economics, University of York,
Brooks, R. EuroQol: the current state of play.
Dolan, P. Modelling valuations for EuroQol health
states. Med Care
1997; 35: 1095–108.
de Wit, GA, Busschbach, J, De Charro, F. Sensitivity and perspective in the valuation of
health status: whose values count?
2000; 9: 109–26.
Dolan, P, Olsen, JA. Distributing Health Care: Economic and Ethical
Issues. Oxford Medical
Brazier, J. Valuing health states for use in cost-effectiveness
2008; 26: 769–79.
Streiner, DL, Norman, GR. Health Measurement Scales: A Practical Guide to Their
Development and Use (3rd edn).
Oxford University Press,
Fitzpatrick, R, Davey, C, Buxton, MJ, Jones, DR. Criteria for assessing patient based outcome
measures for use in clinical trials. Health
Brazier, JE, Deverill, M, Green, C, Harper, R, Booth, A. A review of the use of health status measures in
economic evaluation. Health Technol
Marra, CA, Esdaile, JM, Guh, D, Kopec, JA, Brazier, JE, Koehler, BE, et al. A comparison of four indirect methods of
assessing utility values in rheumatoid arthritis.
2004; 42: 1125–31.
Gleitman, H. Psychology (2nd edn).
Gerard, K, Nicholson, T, Mullee, M, Mehta, R, Roderick, P. EQ–5D versus SF–6D in an older, chronically ill
patient group. Appl Health Econ Health
Walters, SJ, Campbell, MJ. The use of bootstrap methods for analysing
health-related quality of life outcomes (particularly the
SF–36). Health Qual Life Outcomes
2004; 2: 70.
Walters, SJ, Brazier, JE. Comparison of the minimally important difference for
two health state utility measures: EQ–5D and SF–6D.
Qual Life Res
2005; 14: 1523–32.
Barton, GR, Sach, TH, Avery, AJ, Jenkinson, C, Doherty, M, Muir, KR. An assessment of the discriminative ability of the
EQ-5Dindex, SF–6D and EQ VAS, using socio-demographic
factors and clinical conditions. Eur J Health
2008; 9: 237–49.
Kind, P, Dolan, P, Gudex, C, Williams, A. Variations in population health status: results from
a UK national questionnaire survey. BMJ
1998; 316: 736–41.
Fayers, P, Machin, D. Quality of Life: The Assessment, Analysis and
Interpretation of Patient-Reported Outcomes (2nd
edn). John Wiley & Sons,
Claxton, K. The irrelevance of inference: a decision-making
approach to the stochastic evaluation of health care
technologies. J Health Econ
1999; 18: 341–64.
Palmer, S, Davidson, K, Tyrer, P, Gumley, A, Tata, P, Norrie, J, et al. The cost-effectiveness of cognitive behavior
therapy for borderline personality disorder: results from the BOSCOT
trial. J Personal Disord
2006; 20: 466–81.
Byford, S, Barrett, B, Roberts, C, Wilkinson, P, Dubicka, B, Kelvin, RG, et al. Cost-effectiveness of selective serotonin
reuptake inhibitors and routine specialist care with and without
cognitive–behavioural therapy in adolescents with major
depression. Br J Psychiatry
2007; 191: 521–7.
Hakkaart-van Roijen, L, van Straten, A, Al, M, Rutten, F, Donker, M. Cost-utility of brief psychological treatment for
depression and anxiety. Br J Psychiatry
2006; 188: 323–9.
Konig, HH, Roick, C, Angermeyer, MC. Validity of the EQ–5D in assessing and valuing
health status in patients with schizophrenic, schizotypal or delusional
disorders. Eur Psychiatry
2007; 22: 177–87.
van de Willige, G, Wiersma, D, Nienhuis, F, Jenner, J. Changes in quality of life in chronic psychiatric
pateints: a comparison between EuroQol (EQ–5D) and
WHOQoL. Qual Life Res
2005; 14: 441–51.
Brazier, JE, Harper, R, Munro, J, Walters, SJ, Snaith, ML. Generic and condition-specific outcome measures for
people with osteoarthritis of the knee.
1999; 38: 870–7.
Marra, CA, Woolcott, JC, Kopec, JA, Shojania, K, Offer, R, Brazier, JE, et al. A comparison of generic, indirect utility
measures (the HUI2, HUI3, SF–6D, and the EQ–5D) and disease-specific
instruments (the RAQoL and the HAQ) in rheumatoid
arthritis. Soc Sci Med
2005; 60: 1571–82.
Russell, AS, Conner-Spady, B, Mintz, A, Maksymowych, WP. The responsiveness of generic health status measures
as assessed in patients with rheumatoid arthritis receiving
infliximab. J Rheumatol
2003; 30: 941–7.
Feeny, D, Furlong, W, Torrance, GW, Goldsmith, CH, Zhu, Z, DePauw, S, et al. Multi-attribute and single attribute utility
functions for the Health Utilities Index Mark 3 system.
2002; 40: 113–28.
Brazier, JE, Roberts, J, Deverill, M. The estimation of a preference-based measure of
health from the SF–36. J Health Econ
2002; 21: 271–92.
Ware, JE, Sherbourne, C. The MOS 36 item short-form health survey. I
Conceptual framework and item selection. Med
1992; 30: 473–83.
Bryan, S, Longworth, L. Measuring health-related utility: why the disparity
between EQ–5D and SF–6D?
Eur J Health Econ
2005; 6: 253–60.
Lamers, LM, Bouwmans, CAM, van Straten, A, Donker, MCH, Hakkaart, L. Comparison of EQ–5D and SF–6D utilities in mental
health patients. Health Econ
2006; 15: 1229–36.